Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients.
about
The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerSodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancerRadioiodine therapy in differentiated thyroid cancer: the first targeted therapy in oncology.The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.MCM5 as a target of BET inhibitors in thyroid cancer cellsThe Na+/I- symporter (NIS): mechanism and medical impact.The mTOR protein as a target in thyroid cancer.Targeting histone deacetylase in thyroid cancer.Treatment of distant metastases from follicular cell-derived thyroid cancerClinical significance of farnesoid X receptor expression in thyroid neoplasia.Molecular profiles of cancer stem-like cell populations in aggressive thyroid cancers.Flavonoid Fraction of Citrus reticulata Juice Reduces Proliferation and Migration of Anaplastic Thyroid Carcinoma Cells.PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells.Cooperation of histone deacetylase inhibitors SAHA and valproic acid in promoting sodium/iodide symporter expression and function in rat Leydig testicular carcinoma cells.Nucleophosmin delocalization in thyroid tumour cells.Clinical Significance of Hu-Antigen Receptor (HuR) and Cyclooxygenase-2 (COX-2) Expression in Human Malignant and Benign Thyroid Lesions.Somatic amplifications and deletions in genome of papillary thyroid carcinomas.PDE5 Inhibitors-Loaded Nanovesicles: Physico-Chemical Properties and In Vitro Antiproliferative Activity.MicroRNAs as Biomarkers in Thyroid Carcinoma.Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions.Expression and localization of the sodium/iodide symporter (NIS) in testicular cells.Phosphodiesterase type 5 and cancers: progress and challenges.I-131 biokinetics of remnant normal thyroid tissue and residual thyroid cancer in patients with differentiated thyroid cancer: comparison between recombinant human TSH administration and thyroid hormone withdrawal.Effects of nutraceuticals on anaplastic thyroid cancer cells.Expression of YAP1 in aggressive thyroid cancer.Clinical significance of diffuse hepatic visualization and thyroid bed uptake on post-ablative iodine-131 whole body scan in differentiated thyroid cancer.Clinical Significance of EphB4 and EphB6 Expression in Human Malignant and Benign Thyroid Lesions.Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression.Positive effect of RORγt on the prognosis of thyroid papillary carcinoma patients combined with Hashimoto's thyroiditis
P2860
Q27023157-5017E2F4-8148-4ED0-85ED-515A01FFE009Q30367068-07DEADB9-DE90-48ED-BA58-B12D90E5E5A0Q33603806-3AE581FD-C4F4-4F83-A262-BE79D0B0A36DQ34318846-890153CA-76E9-44FF-B50C-9F63007B05B5Q36128415-E7DD9416-FCEC-46E0-A89B-DB2C796A4271Q36965945-BF39F89B-838E-4478-BC45-709F4004DDA8Q37494004-D37CF989-9ADC-4EA0-AA5E-5AD1A9A1AC90Q37894106-D2458B2C-7AE0-4354-851B-17A6910093B0Q38066990-A09B9148-17A7-46C6-BBFD-5B0CD0C93F24Q38370352-4D94E24E-2EDB-45BD-9583-70E66E5EC4AEQ38648804-BC8664EF-9D47-4208-8BBA-D63E1738D145Q38835322-70E6240D-33C6-4F12-BDC7-B0402BD1E860Q38835612-963CA531-8088-460D-9532-6973D8B955A6Q38891514-ED365C66-C6BE-40B7-ABDD-E65F803EB29CQ39157582-6C23248B-3BFF-49A5-9F18-B65E862B4023Q39603964-0F1157B4-68CF-4B11-A3F4-1D8A60326F2DQ40396217-4FF4EC5D-6FAF-451C-842A-8E38F3458DD8Q41088523-78EB6598-778A-4C5E-BE75-278555AE05A4Q41814211-DD6804EC-5D3D-43E8-A22A-3F6BA2E0FE2AQ42361202-6D789AF2-FB15-46F7-B114-76621797021BQ44852149-76722817-97F4-45BB-B762-2B2B9EEC77B4Q46342275-8590A893-77A6-400E-BA01-DB7B4F016D94Q47171803-54FA73FA-B2A9-4D5C-8A13-E426089C6D24Q48177900-18662BA1-48AE-4C95-AFCE-8A04C7B726E2Q48190761-66326F57-0680-4A61-95AA-FB757310CCDEQ48315201-60799DEE-D6E9-488D-B313-8FA3BDD5585CQ50957845-6922F06E-4C37-4CBC-836A-BA3D4BAA175FQ53403455-EA3DF2DC-FD18-4096-B6D8-85032AE0F154Q55058474-54CEE11D-B480-45AB-A725-032FF7937B41Q58733948-4D0F03FB-3822-4F02-BE6C-B4927F7B01C3
P2860
Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Defects in iodide metabolism i ...... -up and treatment of patients.
@ast
Defects in iodide metabolism i ...... -up and treatment of patients.
@en
type
label
Defects in iodide metabolism i ...... -up and treatment of patients.
@ast
Defects in iodide metabolism i ...... -up and treatment of patients.
@en
prefLabel
Defects in iodide metabolism i ...... -up and treatment of patients.
@ast
Defects in iodide metabolism i ...... -up and treatment of patients.
@en
P2093
P356
P1476
Defects in iodide metabolism i ...... -up and treatment of patients.
@en
P2093
Diego Russo
Jean-Michel Bidart
Ludovic Lacroix
Martin Schlumberger
Sebastiano Filetti
P304
P356
10.1038/NCPENDMET0449
P577
2007-03-01T00:00:00Z